SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month High - Time to Buy?

Key Points

• SELLAS (SLS) reached a new 52-week high at $5.42 (last $5.36) on heavy volume (~4.998M shares), trading up about 8.7%; market cap is roughly $782M and the 50-/200-day moving averages are $3.96 and $2.56, respectively.
• Analyst coverage is mixed — Weiss Ratings reaffirmed a "sell (d-)," while the Street shows one Buy and one Sell for a consensus Hold rating and a $7.00 consensus price target.
• SELLAS is a clinical-stage biopharma focused on WT1-targeted cellular immunotherapies, with lead candidate galinpepimut-S (GPS), a multi-peptide vaccine aimed at WT1-positive cancers.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) hit a new 52-week high on Tuesday . The stock traded as high as $5.42 and last traded at $5.36, with a volume of 4998925 shares. The stock had previously closed at $5.05.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $7.00.

SELLAS Life Sciences Group Trading Up 8.7%

The firm has a market cap of $782.01 million, a P/E ratio of -19.61 and a beta of 2.27. The business has a 50-day moving average price of $3.96 and a 200-day moving average price of $2.56.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently modified their holdings of the business. Axxcess Wealth Management LLC purchased a new stake in SELLAS Life Sciences Group during the third quarter worth $26,000. Larson Financial Group LLC bought a new position in shares of SELLAS Life Sciences Group in the 4th quarter worth $26,000. BNP Paribas Financial Markets lifted its stake in shares of SELLAS Life Sciences Group by 89.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company's stock worth $32,000 after purchasing an additional 9,299 shares during the last quarter. Concurrent Investment Advisors LLC bought a new stake in SELLAS Life Sciences Group during the fourth quarter valued at about $38,000. Finally, Beacon Pointe Advisors LLC purchased a new position in SELLAS Life Sciences Group in the fourth quarter valued at about $38,000. 17.38% of the stock is currently owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.